GlassScriptPhysician profile
Emir Kurtovic
NPI 1952783169
$1,494.45
in general payments reported to CMS, 2019-2025
20 companies · $51.05 in 2025
The $51.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $147 · 2021: $262 · 2022: $363 · 2023: $283 · 2024: $126 · 2025: $51.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $315.88 | 2021-2023 | Veklury |
| Ucb, INC. | $217.49 | 2021-2025 | Briviact, Fintepla |
| Janssen Pharmaceuticals, INC | $193.17 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.29 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Amarin Pharma, INC. | $98.49 | 2020 | |
| Pfizer INC. | $74.82 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $63.14 | 2023 | Epidiolex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.64 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $59.90 | 2021-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $58.37 | 2021-2022 | |
| Smith+Nephew, INC. | $50.92 | 2024 | Collagenase Santyl |
| Novo Nordisk INC | $30.07 | 2019 | |
| Abbvie INC. | $29.93 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.58 | 2020-2024 | Eliquis |
| Ultragenyx Pharmaceutical INC. | $18.46 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $15.24 | 2023 | Xerava |
| Ferring Pharmaceuticals INC. | $14.86 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.49 | 2019 | |
| Penumbra, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emir Kurtovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.